ALLMedicine™ Primary Pulmonary Hypertension Center

Mar 10th, 2023 - Introduction: Primary pulmonary hypertension, now known as idiopathic pulmonary arterial hypertension (IPAH), a subgroup of pulmonary arterial hypertension (PAH), is a rare disorder characterized by severe morbidity and high mortality rates. There...

Mar 7th, 2023 - To study the hemodynamic consequences of an open-lung high-frequency oscillatory ventilation (HFOV) strategy in patients with an underlying cardiac anomaly with or without intracardiac shunt or primary pulmonary hypertension with severe lung injur...

Mar 6th, 2023 - We propose a randomized trial to determine the safety and effectiveness of aerobic exercise for patients who have primary pulmonary hypertension (PH) or PH secondary to interstitial lung disease (ILD). This project will be the first in a series of...

Feb 7th, 2023 - Practice Essentials Idiopathic pulmonary artery hypertension (IPAH), previously referred to as primary pulmonary hypertension (PPH), is a relatively recently described entity with an unclear etiology. Because many of the symptoms of IPAH are nonsp...

Feb 7th, 2023 - Practice Essentials Idiopathic pulmonary artery hypertension (IPAH), previously referred to as primary pulmonary hypertension (PPH), is a relatively recently described entity with an unclear etiology. Because many of the symptoms of IPAH are nonsp...

Mar 10th, 2023 - Introduction: Primary pulmonary hypertension, now known as idiopathic pulmonary arterial hypertension (IPAH), a subgroup of pulmonary arterial hypertension (PAH), is a rare disorder characterized by severe morbidity and high mortality rates. There...

Mar 6th, 2023 - We propose a randomized trial to determine the safety and effectiveness of aerobic exercise for patients who have primary pulmonary hypertension (PH) or PH secondary to interstitial lung disease (ILD). This project will be the first in a series of...

Aug 19th, 2022 - A systematic review was conducted to determine the risk/associated factors for pulmonary arterial hypertension in systemic sclerosis, including clinical/disease characteristics, antibody status, test results and biomarkers. The frequency of public...

Feb 23rd, 2022 - Myocardial infarction is a serious common disease in human beings. Although many patients with acute myocardial infarction survive with the improvement of medical technology in recent years, studies have shown that cardiac remodeling caused by myo...

Jan 20th, 2021 - Primary whose mechanisms are incompletely known, is another vascular disease entity recently described in chronic kidney disease particularly in patients undergoing haemodialysis. It corresponds to 5th subtype of World Symposium on Pulmonary Hyper...

Aug 16th, 2015 - I have looked into my genome and seen ... nothing much to worry about. I carry 15 rare genetic variants that have been associated with some form of disease, but I am heterozygous for all of them -- I have one intact copy of the same gene. So I car...

May 19th, 2014 - Endothelin inhibitors Endothelin inhibitors also may play a role in vascular protection. Endothelin is secreted in scleroderma and is a potent vasoconstrictor.

Apr 20th, 2012 - Answer Right ventricular hypertrophy Discussion In this tracing, QRS axis tends to the right axis deviation (RAD), which should make one think of right ventricular hypertrophy (RVH) first. After the RAD, all other diagnostic features of RVH are fo...

Dec 29th, 2011 - Question: A woman developed primary pulmonary hypertension (PPH) 4 years after she had stopped using the prescription weight-loss drug, fenfluramine. The drug is known to cause valvular heart lesions as well as PPH.

Dec 29th, 2011 - Question: A woman developed primary pulmonary hypertension (PPH) 4 years after she had stopped using the prescription weight-loss drug, fenfluramine. The drug is known to cause valvular heart lesions as well as PPH.